<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>t1501154_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 10.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">CONFIDENTIAL</FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">EXECUTION VERSION</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>AMENDMENT No. 2 to LICENSE AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.05pt">This AMENDMENT NO. 2
to LICENSE AGREEMENT (this &ldquo;<B>Amendment No. 2</B>&rdquo;) is made and entered into effective as of May 11, 2015 (the &ldquo;<B>Amendment
No. 2 Effective Date</B>&rdquo;), by and between Mirna Therapeutics, Inc., a Delaware corporation with offices at 2150 Woodward
Street, Suite 100, Austin, Texas 78744 (&ldquo;<B>MirnaRx</B>&rdquo;), and Marina Biotech, Inc., a Delaware corporation with offices
c/o Pryor Cashman LLP, 7 Times Square, New York, New York 10036 (&ldquo;<B>Marina Bio</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, MirnaRx
and Marina Bio are parties to a License Agreement dated December 22, 2011, as amended by the Letter Amendment dated November 16,
2012, and Amendment No. 1, dated December 27, 2013 (&ldquo;<B>Amendment No. 1</B>&rdquo;)<B> </B>and as further supplemented by
that certain Amendment Side Letter referred to in Amendment No.1, dated January 9, 2014 (collectively, the &ldquo;<B>License Agreement</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>pursuant
to the License Agreement, Marina Bio granted to MirnaRx a license under Marina&rsquo; Bio&rsquo;s technology and intellectual property
rights relating to Marina Bio&rsquo;s liposomal delivery technology known as NOV340 (the &ldquo;<B>Marina Technology</B>&rdquo;),
to develop and commercialize drug products incorporating such Marina Technology in combination with MirnaRx&rsquo;s proprietary
compound miR-34, and other specified compounds selected by MirnaRX pursuant to the terms of the License Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.05pt"><B>WHEREAS</B>, MirnaRx
and Marina Bio desire to amend the License Agreement to modify the consideration payable by MirnaRx to Marina Bio with respect
to development of products containing miR-34 and using the Marina Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.05pt"><B>NOW THEREFORE</B>,
in consideration of the foregoing premises, the mutual promises and covenants of the Parties hereinafter set forth, and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally
bound, do hereby agree as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment
of License Agreement</U>.&nbsp;&nbsp;&nbsp;In accordance with Section 12.1 of the License Agreement, the Parties hereby agree to amend the License
Agreement, effective as of the Amendment No. 2 Effective Date, in accordance with the remainder of this Section 1. Capitalized
terms not defined in this Amendment No. 2 shall have the meaning given to those terms in the License Agreement. With the exception
of those sections of the License Agreement that are expressly amended by this Amendment No. 2, the remainder of the License Agreement
as in effect prior to the date hereof shall remain in full force and effect as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
5.3(c) (as amended by Amendment No. 1) shall be amended and restated in its entirety with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3(c) Notwithstanding
Sections 5.3(a) and 5.3(b) and the milestone table above, and solely with respect to Licensed Products containing or incorporating
miR-34:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i) no Milestone Payment
shall be payable by MirnaRx for (A) achievement of the Milestone Event in clause (i)(3) of the milestone table above, or (B) any
Additional Indications pursuant to clause (ii)(1) of the milestone table above; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii) with respect to the
Milestone Payment payable to Marina Bio upon the date the first patient is dosed in the first Phase 2 trial for such Licensed Product
pursuant to clause (i)(2) of the milestone table above, MirnaRx may elect to pre-pay such Milestone Payment to Marina Bio prior
to the achievement of such Milestone Event (the &ldquo;<B>miR-34 Prepayment</B>&rdquo;), and if such miR-34 Prepayment is made
to Marina Bio on or before May 13, 2015<B> </B>(the &ldquo;<B>Prepayment Date</B>&rdquo;), such Milestone Payment shall be reduced
to $400,000. Marina Bio agrees that if the miR-34 Prepayment is made on or before the Prepayment Date, such payment shall constitute
full and complete satisfaction of the Milestone Payment due under clause (i)(2) of the milestone table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">For clarity, Sections 5.3(a)
and 5.3(b) and the milestone table shall apply in full to all Licensed Products other than any Licensed Product containing or incorporating
miR-34, unless the Parties mutually agree otherwise in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Other Amendments</U>.&nbsp;&nbsp;&nbsp;Except as specifically modified herein, the remaining terms of the License Agreement shall remain in full
force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prepayment</U>.&nbsp;&nbsp;&nbsp;MirnaRx hereby agrees to pay to Marina Bio, within five (5) business days after the Amendment No. 2 Effective Date, an amount equal
to Four Hundred Thousand Dollars ($400,000), representing full satisfaction of the Milestone Payment due under Section 5.3(a)(i)(2)
of the License Agreement for a Licensed Product containing the Selected MirnaRx Compound miR-34, in accordance with Section 5.3(c)
of the License Agreement, as amended by this Amendment No. 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts;
Facsimile Execution</U>.&nbsp;&nbsp;&nbsp;This Amendment No. 2 may be executed in two (2) or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. This Amendment No. 2 may be executed by facsimile
signatures and such signatures shall be deemed to bind each Party as if they were original signatures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF,</B> the Parties have caused this Amendment No. 2 to be executed by their respective officers thereunto duly authorized
as of the Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Mirna Therapeutics, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Marina Biotech, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Signature : </TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Dr. Paul Lammers</TD>
    <TD>&nbsp;</TD>
    <TD>Signature : </TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ J. Michael French</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name : </TD>
    <TD>Dr. Paul Lammers</TD>
    <TD>&nbsp;</TD>
    <TD>Name : </TD>
    <TD>J. Michael French</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Title : </TD>
    <TD>President &amp; CEO</TD>
    <TD>&nbsp;</TD>
    <TD>Title : </TD>
    <TD>President &amp; CEO</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal"><I>[Signature
page to Amendment No. 2 to License Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
